HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OEHHA

This article was originally published in The Rose Sheet

Executive Summary

Propylene glycol mono-t-butyl ether, a chemical used as a solvent in nail polish lacquers, cleaners and other water-reducible coatings, has been added to the California Prop 65 list of chemicals known to the state to cause cancer, Office of Environmental Health Hazard Assessment reports. Agency issued a notice of intent to list the chemical in April, citing an NTP study as its basis. Last year, NTP reviewed a technical report on propylene glycol mono-t-butyl ether and determined there is "equivocal evidence" of carcinogenic activity of the chemical in F344/N rats in a two-year inhalation study (1"The Rose Sheet" April 21, 2003, p. 7)...

You may also be interested in...



TEA Carcinogenic Link Suggested By Two Year NTP Study

Triethanolamine demonstrated "some evidence" of carcinogenic activity in a two-year dermal study of female B6C3F1 mice and "equivocal evidence" of carcinogenic activity in male mice, the National Toxicology Program states in a 1draft technical report on the ingredient

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel